Guselkumab

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1108 publications

Clinical outcomes following switch from risankizumab to guselkumab in Crohn's disease.

Clinical outcomes following switch from risankizumab to guselkumab in Crohn's disease.

Journal: Journal of Crohn's & colitis
Published: August 13, 2026

Refractory verrucous psoriasis achieving clearance with guselkumab and subsequent response to excimer therapy.

Refractory verrucous psoriasis achieving clearance with guselkumab and subsequent response to excimer therapy.

Journal: JAAD case reports
Published: August 09, 2026

PANCCO Clinical Practice Guideline Update for the treatment of ulcerative colitis in adults

PANCCO Clinical Practice Guideline Update for the treatment of ulcerative colitis in adults

Journal: Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru
Published: July 25, 2026

The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis-Real-World Evidence up to 64 Weeks of Therapy.

The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis-Real-World Evidence up to 64 Weeks of Therapy.

Journal: Medical sciences (Basel, Switzerland)
Published: July 24, 2026

Beyond the Usual Targets: A Case Report of Overcoming IL-23 and IL-17A Biologic Nonresponse in Palmoplantar Psoriasis With Brodalumab.

Beyond the Usual Targets: A Case Report of Overcoming IL-23 and IL-17A Biologic Nonresponse in Palmoplantar Psoriasis With Brodalumab.

Journal: The Journal of clinical and aesthetic dermatology
Published: July 22, 2026

Interstitial Lung Disease Induced by Monoclonal Antibodies for Psoriatic Arthritis, a Double Hit: A Case Report with a Literature and Clinical Trial Review.

Interstitial Lung Disease Induced by Monoclonal Antibodies for Psoriatic Arthritis, a Double Hit: A Case Report with a Literature and Clinical Trial Review.

Journal: Pulmonary therapy
Published: July 12, 2026

Propensity-Matched Case Control Study of Anti-Interleukin-23 Therapies in Clostridioides difficile Infection.

Propensity-Matched Case Control Study of Anti-Interleukin-23 Therapies in Clostridioides difficile Infection.

Journal: Research square
Published: July 10, 2026

Guselkumab Every 4 Weeks as a Real-World Therapeutic Option for Psoriatic Arthritis Patients at High Risk of Joint Damage.

Guselkumab Every 4 Weeks as a Real-World Therapeutic Option for Psoriatic Arthritis Patients at High Risk of Joint Damage.

Journal: Clinics and practice
Published: July 08, 2026

Safe seroconversion after receiving measles, mumps, and rubella live vaccine during guselkumab treatment for psoriasis.

Safe seroconversion after receiving measles, mumps, and rubella live vaccine during guselkumab treatment for psoriasis.

Journal: JAAD case reports
Published: July 02, 2026

Ostraceous psoriasis in end-stage renal disease: A delayed phenotype switch from dupilumab treated with guselkumab.

Ostraceous psoriasis in end-stage renal disease: A delayed phenotype switch from dupilumab treated with guselkumab.

Journal: JAAD case reports
Published: July 01, 2026

Clinical outcomes following switch from risankizumab to guselkumab in Crohn's disease: a real-world case series.

Clinical outcomes following switch from risankizumab to guselkumab in Crohn's disease: a real-world case series.

Journal: Journal of Crohn's & colitis
Published: June 26, 2026

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Journal: The Cochrane database of systematic reviews
Published: June 23, 2026
Showing 1-12 of 1,108

Last Updated: 09/26/2026